Q3 2024 Aurinia Pharmaceuticals Inc Earnings Call
Speaker Change: Thank you for your patience. Please stay on the line for the next available operator.
[music]
Speaker Change: Thank you for your patience. Please stay on the line for the next available operator.
"-music playing..."
Speaker Change: Thank you for your patience. Please stay on the line for the next available operator.
Music
Speaker Change: Thank you for your patience. Please stay on the line for the next available operator.
Hello, may I have the name of your conference?
Hello, can you hear me?
Greenleaf, Gregory Keenan, Joseph Miller, Andrea Christopher, Gregory Keenan, Joseph
Speaker Change: UPCR down to an acceptable level and many times a physician is then taking the patient off of the drug.
Speaker Change: not just our drug, any medication that they might be on.
Speaker Change: If you PCR flares, then they're putting them back on drug. And, you know, whether you look at EULAR or the Cadego guidelines that were recently just updated, or we've got the impending ACR guidelines that we're hoping to get an eye on at this year's ACR meeting.
I think the consistency of putting patients on drug
Speaker Change: greeting aggressively at early signs of UPC of elevated protein urine in the urine and Keeping patients on drug for three to five years and not doing these treating flares is It's going to be absolutely consistent least our prediction
Speaker Change: and we see that as a great opportunity as the market moves forward that will of course
Speaker Change: affect restarts, but will also have a very positive impact on things like persistency. So we think there's wind in our sails on both fronts at this stage and why we see the importance of
Speaker Change: growing importance of hospital-based sales and restarts. Greg, on the light LN registry, what would you add there? We're starting to gain insight in the real world as to who's receiving this treatment, and importantly, a larger proportion than typically is observed in clinical trials we see of African Americans that are receiving the treatment. Most recent data cut was over 35% of the participants are African American or Black. And then the other thing that we do observe is different combinations of treatments along with butokinase. We're starting to see at least a little bit of combinations with Benlista and just a few with anaphrodite.
Speaker Change: So we think over time we'll gain more insight as to how people are using lutekinase in the real world. For now, we're pleased with the number of patients we have and the success of the registry.
Got it. All helpful, perspective. Thanks for taking our questions.
Thank you, sir.
Speaker Change: Your next question comes from Olivia Bray from Canto Office, Gerald. Your line is open.
Olivia Bray: Hi, good morning. Thank you for the questions. You guys have shown some really nice potency data for AUR200, so how are you thinking about the potential dose levels that you want to test in the clinic?
Speaker Change: You know, I guess what I'm getting at is we've seen in this class that higher doses can have some safety or tolerability issues.
Speaker Change: But I'd also think that you guys could probably test lower doses with a higher potency drug
Speaker Change: Olivia, I think the bottom line, and I'll take this question for Greg, is we're in the single ascending dose and multi ascending dose studies now, or we'll be moving into the multi ascending dose trial. And these are, they're all great questions. They're all things we're gonna figure out in human beings in these studies. So we look forward to reporting them to you as we get data.
Okay, understood. Thanks, Peter.
Thank you.
Speaker Change: Your next question will come from the line of Wilsockin from Learinc Partners. Your line is open.
Speaker Change: Great. Hey, guys. Thanks for taking our question here. We just have two quick ones. First on Luke Kynes, can you just provide a bit more color commentary on the environment in the third quarter? We can appreciate that sales remain pretty strong, but the regression in PSFs was a bit more acute than we've seen before, just comparing to last year.
Speaker Change: And then on AUR200, there's been a lot of buzz in the anti-april space, with yet another asset entering the ring last week. So can you just remind us how you're thinking about competitive differentiation and what indications you might be thinking about? Thank you.
Speaker Change: Yeah, I'll answer the last one first. Let us actually get the data from the SADMAD studies and you know See what they tell us before we come forward tell you what indications we're trying to target, etc We got to get some human clinical data here. So I'm not trying to in any way Dodge the question I think we got to get smart once we see these trials and then Move in the direction of the indications we want to go after so more to come on your first Question which centered on PSFs as I said previously Yeah, I mean 3q we always have a summer dynamic But I want to dig too much into that because I do think there was a little bit of that More and more we are seeing the combination of PSFs alongside of research
Speaker Change: but understand patients start outside of our process too and that's restarts and in the hospital setting where they're not using our process. And if you look at those in combination the robust, the growth quarter over quarter was was robust.
Speaker Change: And as I said, Q4, when we report it, we'll actually be able to show you life numbers on Q4 last year for PSFs, Q4 for hospital starts, and Q4 for new patient restarts. And those in combination are where we're moving to really start looking at.
Speaker Change: in aggregate, the new patients getting on drug within the quarter.
Great. Thank you for that commentary.
Speaker Change: There are no further questions at this time, so I would like to hand back to Peter Greenleaf, CEO, for closing remarks.
Peter Greenleaf: Thank you operator and thank you everyone for joining the call today. We look forward to continuing to report our progress as we continue to move the business forward and build the business for the long term. Thank you very much for your time.
Speaker Change: That does conclude our conference for today. Thank you for participating, you may now all disconnect.